Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Cancer Discovery
|
June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Alexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Cancer Discovery
|
January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Hubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Nature Medicine
|
February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer
Melissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Cancer Discovery
|
June 3, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Alexander Drilon, Manish R Sharma, Melissa L Johnson, et al.
Cancer Discovery
|
January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth
Hubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Nature Medicine
|
February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Page
of 10